Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and Usher syndrome

Archives of Ophthalmology

Volumn 128, Issue 9, 2010, Pages 1146-1150

  Genead, Mohamed A ^a   Fishman, Gerald A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; EYE DROPS; SULFONAMIDE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULOPATHY; RETINITIS PIGMENTOSA; USHER SYNDROME; VISUAL ACUITY; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RETINA; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; CARBONIC ANHYDRASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; RETINA; RETINITIS PIGMENTOSA; RETROSPECTIVE STUDIES; SULFONAMIDES; THIOPHENES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; USHER SYNDROMES; VISUAL ACUITY; YOUNG ADULT;

EID: 77956997686     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.172     Document Type: Article

References (26)

1. Marmor MF, Aguirre G, Arden GB, et al. Retinitis pigmentosa: a symposium on terminology and methods of examination. Ophthalmology. 1983;90(2):126-131.
2. Rosenberg T, Haim M, Hauch AM, Parving A. The prevalence of Usher syndrome and other retinal dystrophy - hearing impairment associations. Clin Genet. 1997;51(5):314-321.
3. Walia S, Fishman GA, Hajali M. Prevalence of cystic macular lesions in patients with Usher II syndrome. Eye (Lond). 2009;23(5):1206-1209.
4. Hajali M, Fishman GA. The prevalence of cystoid macular edema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination. Eye (Lond). 2009;23(4):915-919.
5. Fetkenhour CL, Choromokos E, Weinstein J, Shoch D. Cystoid macular edema in retinitis pigmentosa. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3, pt 1):OP515-OP521.
6. Fishman GA, Fishman M, Maggiano JM. Macular lesions associated with retinitis pigmentosa. Arch Ophthalmol. 1977;95(5):798-803.
7. Ffytche TJ. Cystoid maculopathy in retinitis pigmentosa. Trans Ophthalmol Soc U K. 1972;92:265-283.
8. Wolfensberger TJ, Aptsiauri N, Godley B, Downes S, Bird AC. Antiretinal antibodies associated with cystoid macular edema [in German]. Klin Monatsbl Augenheilkd. 2000;216(5):283-285.
9. Fishman GA, Gilbert LD, Anderson RJ, Marmor MF, Weleber RG, Viana MA. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology. 1994;101(4):687-693.
10. Wolfensberger TJ. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol. 1999;97(3-4):387-397.
11. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106(9):1190-1195.
12. Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107(10):1445-1452.
13. Grover S, Fishman GA, Fiscella RG, Adelman AE. Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Retina. 1997;17(3):222-231.
14. Apushkin MA, Fishman GA, Grover S, Janowicz MJ. Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina. 2007;27(8):1112-1118.
15. Fishman GA, Glenn AM, Gilbert LD. Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa. Arch Ophthalmol. 1993;111(12):1640-1646.
16. Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Br J Ophthalmol. 2007;91(6):743-745.
17. Genead MA, Fishman GA, Walia S. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol. 2010;128(2):190-197.
18. Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141(5):850-858.
19. Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol. 2006;124(2):193-198. (Pubitemid 43247068)
20. Grover S, Fishman GA, Gilbert LD, Anderson RJ. Reproducibility of visual acuity measurements in patients with retinitis pigmentosa. Retina. 1997;17(1): 33-37.
21. Greenstein VC, Holopigian K, Siderides E, Seiple W, Carr RE. The effects of acetazolamide on visual function in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1993;34(1):269-273.
22. Marmor MF, Abdul-Rahim AS, Cohen DS. The effect of metabolic inhibitors on retinal adhesion and subretinal fluid resorption. Invest Ophthalmol Vis Sci. 1980; 19(8):893-903.
23. Tsuboi S, Pederson JE. Experimental retinal detachment, X: effect of acetazol-amide on vitreous fluorescein disappearance. Arch Ophthalmol. 1985;103(10): 1557-1558.
24. Kawasaki K, Mukoh S, Yonemura D, Fujii S, Segawa Y. Acetazolamide-induced changes of the membrane potentials of the retinal pigment epithelial cell. Doc Ophthalmol. 1986;63(4):375-381.
25. London NJS, Fung AE. Evaluating the nerve and macular thickness measurements of the Optovue RTVue, Zeiss Stratus, and Cirrus OCTs [e-abstract 4241]. Invest Ophthalmol Vis Sci. 2008;49:A334.
26. Fullerton JM, Kim JE, Xiang Q, Szabo A. Comparison of spectral domain OCT and time domain OCT for measurements of retinal thickness [e-abstract 1073]. Invest Ophthalmol Vis Sci. 2009;50:D1017.